Novel Hyaluronic Acid Coating for Potential Use in Glucose Sensor Design

Praveen, S; Hanumantha, Ravikumar; Belovich, Joanne M.; Davis, Brian L.

doi:10.1089/152091503765691893

Cited by 25 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vadgama and coworkers applied a micro-flow system that prevents adherence of biomolecules by the continuous flow of a chelating buffer over the surface, which was reported to provide good blood:tissue glucose concentration correlation (Rigby et al, 1999). Another system that shows excellent promise is the use of biomimicry with a humic acid, hyaluronic acid or phosphorylcholine coating (Praveen et al, 2003;Galeska et al, 2001). The phosphorylcholine system, based on the work by Ishihara (1997) for an in vivo glucose sensor reported steady current and appropriate response to changing glucose (Yang et al, 2000b).…”

Section: Initial Inflammatory Response Eventsmentioning

confidence: 99%

Biosensors for real-time in vivo measurements

Wilson

Gifford

2005

Biosensors and Bioelectronics

592

351

View full text Add to dashboard Cite

Section: Initial Inflammatory Response Eventsmentioning

confidence: 99%

Biosensors for real-time in vivo measurements

Wilson

Gifford

2005

Biosensors and Bioelectronics

592

351

View full text Add to dashboard Cite

“…In general, more hydrophilic polymers such as phosphorylcholine [315,349,350], 2-methacryloxyethyl phosphorylcholine [351][352][353], PEG [354], cross-linked PEG [355], PEG introduced into a hydroxyethylmethacrylate and ethylene dimethacrylate chain, polyvinyl alcohol [356] and water-rich hydrogels [357] have been reported more recently to reduce protein adsorption on sensor surfaces and thereby mitigate the foreign body reaction. Less frequently, hyaluronic acid [358][359][360][361] and humic acid [358] have been utilized in outer biocompatible coatings. Turning to surface morphology, the impact of introducing porosity into biocompatible coatings onto function of implanted glucose sensors has been investigated by several groups [315,[362][363][364][365][366][367].…”

Section: Biocompatible Coatingmentioning

confidence: 99%

Electrochemical Glucose Biosensors for Diabetes Care

Ocvirk¹,

Buck²,

DuVall³

2016

Trends in Bioelectroanalysis

View full text Add to dashboard Cite

Blood glucose monitoring (BGM) is the most successful application of electrochemical biosensor technology and has motivated tremendous improvements in biology, chemistry, measurement, and fabrication methods of biosensors. The performance of electrochemical biosensors used for BGM has improved greatly over the last four decades. Technological advance has allowed to measure blood glucose (BG) over a wide range of glucose concentration, a wide temperature and hematocrit range in the presence of an abundance of interfering substances with ever-increasing accuracy, and precision in minute sample volumes. The use of optimized enzymes, mediators, and electrochemical measurement methods enables this tremendous progress in performance. Continuous glucose monitoring (CGM) systems based on minimally invasive amperometric sensors, inserted into the subcutaneous tissue, have significantly improved over initial offerings over the last 15 years with regard to time of use, accuracy, reliability, and convenience due to a multitude of parallel advances: materials needed for enzyme immobilization, polymeric cover membranes, and biocompatible coatings needed to tackle the response by the complex body interface have been developed; wireless transfer and processing of unprecedented data volume have been established; effortless and painless insertion schemes of ever smaller sensors have been realized in order to overcome the concerns of persons with diabetes (PwDs) to use a minimally invasive sensor; and scalable manufacturing technologies of miniaturized minimally invasive sensors have allowed for ever improved reproducibility and increased production volume. Looking ahead, the demands on blood glucose system performance G. Ocvirk (*) Roche Diabetes Care GmbH, Mannheim, Germany e-mail: gregor.ocvirk@roche.com H. Buck and S.H. DuVall Roche Diabetes Care, Inc., Indianapolis, IN, USA e-mail: harvey.buck@roche.com; stacy.duvall@roche.com are expected to grow even as the pressures to lower the cost of systems increase. The drive for the future is to continue to push the limits on system performance under real-life conditions while lowering cost, all while finding ways to provide the best medical value to PwDs and healthcare providers. Technical issues of commercially available CGM sensors remain to be solved which currently impede reliable hypo-and hyperglycemic alarms, safe insulin dosing recommendations, or insulin pump control at any time of use. It is realistic to assume that continuous glucose monitoring (CGM) systems will be adopted in the future by a larger population of PwDs. Yet it is also clear that BGM systems will remain a major choice of the great majority of PwDs on a global scale. This review offers a technical overview about user, system, and major regulatory requirements and available suitable sensor technology and demonstrated performance of electrochemical BGM and CGM systems from an industrial R&D perspective.

show abstract

“…Ранее реакции на инородное тело пытались пре-дотвратить, покрывая сенсор биосовместимыми ма-териалами -Nafi on [55], гиалуроновой кислотой [56] и гуминовой кислотой [46]. Однако иммунный ответ организма развивался даже при использова-нии биосовместимых материалов, т.е.…”

Section: воспаление реакция на инородное тело и биообрастаниеunclassified

Continuous glucose monitoring technologies: state of the art and future perspectives in view of artificial pancreas

Владимирович¹,

Иванович²,

Андреевна³

et al. 2015

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Continuous glucose monitoring (CGM) - a relatively new and rapidly developing technology of optimization glycemic control in patients with diabetes. The efficiency of the use of CGM for improving glycemic level in many clinical situations (asymptomatic hypoglycemia, high blood glucose variability, etc.). In the long term, CGM treated as a mandatory component of the «artificial pancreas» - an insulin pump with a closed-loop control infusion of insulin depending on the concentration of glucose in the blood. However, the modern technology such as CGM could not be used, as a data source to control closed-loop insulin pump (artificial pancreas), because of the significant limitations and lack of precision. In further development of technologies CGM, obviously, will address three main objectives: increased service life of sensors for the detection of glucose, improving the accuracy of measurement results and ease of use for patients. This article describes the main technological solutions of modern devices for CGM and promising directions for further developments in this field, their potential advantages and disadvantages, including in the light of the prospects for further integrating them into an «artificial pancreas».

show abstract

Novel Hyaluronic Acid Coating for Potential Use in Glucose Sensor Design

Cited by 25 publications

References 12 publications

Biosensors for real-time in vivo measurements

Biosensors for real-time in vivo measurements

Electrochemical Glucose Biosensors for Diabetes Care

Continuous glucose monitoring technologies: state of the art and future perspectives in view of artificial pancreas

Contact Info

Product

Resources

About